You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.
The technology relates to the isolation and genetic analysis of circulating fetal cells from maternal blood.
The companies will validate and commercialize the assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.
The license is part of an ongoing cancer research collaboration between NovellusDx and Christiana Care's Gene Editing Institute.
The deal between GE, the Global Good Fund, and Access Bio is to manufacture and distribute malaria diagnostic technologies in low-resource nations.
The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.
The assay employs nanoplasmonics and protein-signal multiplexing in taking aim at early clinical detection of pancreatic ductal adenocarcinoma.
Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.
The technology uses Thermo Fisher Scientific microarrays to measure transcript levels in order to diagnose rejection of solid organ transplants.
The firm is seeking funding to commercialize a malondialdehyde-acetaldehyde-adduct biomarker ELISA that it believes can help broaden access to cardiac tests.